749138
Last Update Posted: 2010-03-09
Recruiting has ended
All Genders accepted | 18 Years-75 Years |
18 Estimated Participants | No Expanded Access |
Interventional Study | Does not accept healthy volunteers |
Fourteen Day Safety of Low-Dose Tamoxifen in Patients With Chronic Hepatitis C Who Have Failed Standard Medical Therapy
A short 14 day phase 1 study examining 6 monotherapy doses of oral tamoxifen for safety in chronic HCV patients who have failed standard treatment of peginterferon and ribavirin.
Six different dosages of tamoxifen will be given for 14 days with safety and viral loads being measured.
Eligibility
Relevant conditions:
Chronic Hepatitis C
If you aren't sure if you meet the criteria above speak to your healthcare professional. Criteria may be updated but not reflected here, do not hesitate to contact the study if you think are close to fitting criteria.
locations
Data sourced from ClinicalTrials.gov